

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No potential issues were identified.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee noted that although the marketing authorisation for elacestrant is for the 'treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation', a person can have breast cancer after menopause and not identify as a woman. Gender reassignment is a protected characteristic under the Equality Act 2010. The committee highlighted this information in the DG and noted that the

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

Issue date: September 2024

recommendations in the guidance include women, trans men and non-binary people registered female at birth who have been through the menopause, and men.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Yes, as above.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, section 3.19.

Approved by Associate Director (name): ...Emily Crowe.....

Date: 27/09/2024

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

Issue date: September 2024

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

Issue date: September 2024